Target
metastatic breast cancer
1 product
126 abstracts
Abstract
Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial.Org: Westwood, Kansas City, Department of Biostatistics & Data Science, Central Care Cancer Ctr, The University of Kansas Cancer Center,
Abstract
ctDNA as a biomarker in phase II study of tepotinib in advanced solid cancers with MET exon 14 skipping mutation or amplification (KCSG AL19-17).Org: Chungbuk Univeristy Hospital, Chungbuk University College of Medicine, Inje University College of Medicine, Pusan National University School of Medicine, Chonnam National University Hwasun Hospital,
Abstract
Mind the gap: Estimating the opportunity lost due to the gap between FDA and EMA cancer drug approvals.Org: Lifespan Cancer Institute, Brown University School of Medicine-Rhode Island Hospital, Rhode Island Hospital, Stanford University School of Medicine, The University of Texas MD Anderson Cancer Center,
Abstract
Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study.Org: Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, Medical Oncology, Regional University Hospital of Málaga, Málaga, Spain, Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, Paris-Saclay University, Gustave Roussy Cancer Center, Villejuif, France,
Abstract
Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal, or bone metastases in the phase II VISION trial.Org: Asklepios Clinics Munich-Gauting, Delta Hat, Merck N.V.-S.A., Thoracic Oncology Service,
Abstract
STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma.Org: Winship Cancer Institute, Emory University, Atlanta, GA, USA, The Institute of Cancer Research/The Royal Marsden Hospital, Fondazione IRCCS Istituto Nazionale Tumori and University of Milan, Cliniques Universitaires Saint-Luc,
Abstract
Updated interim analysis of a phase I/Ib study of enfortumab vedotin plus cabozantinib in patients with metastatic urothelial carcinoma.Org: Winship Cancer Institute of Emory University, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA,
Abstract
Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study.Org: Barts Health NHS Trust Saint Bartholomew’s Hospital,
Abstract
Clinical-genomic characteristics in patients with EGFR-mutated non-small cell lung cancer harboring MET copy number gains after progression on EGFR-TKI: A report from LC-SCRUM-TRY.Org: Yamaguchi-Ube Medical Center, Iwakuni Clinical Center,
Abstract
Expression of the receptor tyrosine kinase AXL and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma enrolled in the METEOR trial.Org: Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, DFCI/PCC Fellowship Program - Attendings, Yale Cancer Center,
Abstract
Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,
Abstract
FIT-001: A phase 1 clinical trial of the farnesyl transferase inhibitor KO-2806 alone or as part of combination therapy for advanced solid tumors.Org: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Carbone Cancer Center, University of Wisconsin, Madison, WI, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL,
Abstract
Clinical impact of the rapid genomic screening platform for non-small cell lung cancer in Asia-Pacific (LC-SCRUM-AP).Org: Chang Gung Memorial Hospital Linkou Branch, Kuala Lumpur Hospital, Siriraj Hospital, Precision Medicine Asia, PREMIA Holdings (HK) Limited,
Abstract
Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): Subgroup analysis of the phase 2 LITESPARK-013 study.Org: University of Miami Hospital and Clinics, Cancer Research Services, New York Oncology Hematology, Moscow City Clinical Oncology Hospital No. 1, Alexandra General Hospital,
Abstract
A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Indiana University Simon Comprehensive Cancer Center, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, University of Chicago, Chicago, IL, Department of Medicine, Division of Hematology and Oncology, The Medical College of Wisconsin, Milwaukee, WI, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, Mary Crowley Cancer Research, Dallas, TX, AdventHealth Cancer Institute, Orlando, FL, Sarah Cannon Research Institute, Nashville, TN, St. Jude Crosson Cancer Institute/Providence Medical Foundation, Fullerton, CA, Fort Wayne Medical Oncology - West Jefferson Office, Fort Wayne, IN, Scholar Rock Inc., Cambridge, MA, Scholar Rock, Cambridge, MA, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Cabozantinib plus atezolizumab in patients with advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II trial (CABATEN / GETNE-T1914).Org: University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario 12 de Octubre, Imas12, UCM, Hospital Universitario La Paz, IdiPAZ, Hospital Universitario Central de Asturias, ISPA, Catalan Institute of Oncology (ICO-Badalona) Germans Trias i Pujol University Hospital,
Abstract
Impact of CBM588 on gut microbiome composition and dysbiosis in patients receiving frontline immune checkpoint inhibitor (ICI) combinations for metastatic renal cell carcinoma (mRCC).Org: Miyarisan Pharmaceutical Co., Ltd., Saitama, Japan,
Abstract
Biomarker analysis of zanzalintinib in clear cell renal cell carcinoma from STELLAR-001.Org: APHP Hôpital Européen Georges Pompidou and Université Paris Cité, Charles University and Thomayer University Hospital, Institut de Cancérologie Gustave Roussy,
Abstract
Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.Org: University of Malaya Medical Centre, Hospital Umum Sarawak, Hospital Tengku Ampuan Afzan, First Affiliated Hospital of Army Medical University, Huizhou Municipal Central Hospital of Guangdong Province,
Abstract
Amivantamab plus chemotherapy vs chemotherapy as first-line treatment among patients with EGFR exon 20 insertion–mutated advanced non-small cell lung cancer (NSCLC): PAPILLON Chinese subgroup analysis.Org: Janssen China Research and Development, Xi'an Janssen Pharmaceutical Ltd,
Abstract
A phase 1/2, open label study of amivantamab in combination with tyrosine kinase inhibitors among participants with advanced NSCLC harboring ALK, ROS1, and RET gene fusions.Org: University of Michigan - Rogel Cancer Center,
Abstract
Amivantamab plus capmatinib in advanced non-small cell lung cancer (NSCLC) harboring MET alterations: Recommended phase 2 combination dose and preliminary dose-escalation results from the phase 1/2 METalmark study.Org: Virginia Health Specialists, Fairfax, VA, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Janssen Research & Development, San Diego, CA, Janssen Research & Development, Bridgewater, NJ, Janssen Research & Development, Beerse, Belgium,
Abstract
Immune infiltrate characterization and differential gene expression by RNA-sequencing analysis in patients with oncogene-addicted NSCLC with early progression under targeted therapy.Org: Genomic Platform and Biobank, AMMICa UAR3655/US23, Gustave Roussy, Cancer Campus,
Abstract
Prognostic genomic signatures in patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES study).Org: Fondazione Policlinico Universitario "A. Gemelli" - IRCCS - UOC Oncologia Medica, Roma, Italy, Medical Oncology, Azienda Ospedaliera ARNAS Garibaldi, Catania, Italy, Medical Oncology Deparment, Istituto Europeo di Oncologia – IRCCS, Milan, Italy, Clinical Sperimental Abdominal Oncology Unit, Istituto Nazionale Tumori – IRCCS Fondazione G. Pascale, Napoli, Italy, Oncology Unit, Fondazione Casa Sollievo della Sofferenza – IRCCS, San Giovanni Rotondo, Italy,
Abstract
Real-world outcomes comparison between the MET inhibitors (METi) capmatinib and tepotinib in patients with stage IV non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation.Org: Mayo Clinic Florida, Mayo Clinic,
Abstract
STELLAR-303: A randomized phase 3 study of zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated metastatic colorectal cancer.Org: Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC,
Abstract
Utilizing stereotactic body radiation therapy in combination with tyrosine kinase inhibitors for therapeutic benefit in thyroid cancer.Org: Northwell Health Department of Radiation Medicine,
Abstract
Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2.Org: Virginia Health Specialists, Fairfax, VA, University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA, Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Janssen-Cilag Pharmaceutical, Pefki, Greece, Janssen Research & Development, Shanghai, China,
Abstract
Effect of longitudinal ctDNA monitoring with resistance genomic signatures on prognostication in patients with EGFR-mutated advanced NSCLC.Org: Pune, Advanced Centre for Treatment Research and Education in Cancer, Navi Mumbai, Cupertino, CA,
Abstract
MET exon 14 skipping in NSCLC: An unMET Indian need.Org: Rajiv Gandhi Cancer Institute and Research Center, Tata Memorial Hospital, Tata Memorial Centre,
Abstract
Enhancing the efficacy of anti-PD-L1 therapy by cabozantinib in the treatment of advanced esophageal squamous cell carcinoma (ESCC): Rationales from a preclinical study.Org: National Taiwan University Cancer Center/Hospital, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, National Taiwan University Hospital Yunlin Branch,
Abstract
Real-world effectiveness and safety of amivantamab for exon 20 EGFR-mutant non-small cell lung cancer (NSCLC) in French early access program: Amexon 20 GFPC.Org: Hospices Civils of Lyon, Hospital Morvan, Hospital Albert Calmette, CHU Saint-Denis La Réunion, Saint-Denis,
Abstract
Evaluating progression-free survival of EGFR exon 20ins in patients with advanced non-small lung cancer receiving EGFR inhibitors: A real-world data study.Org: BioSpark AI Technologies,
Abstract
Implementing personalized lung cancer care with spatial profiling, patient derived organoids, and rationally designed drug testing.Org: University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, University of Colorado School of Medicine, Veterans Affairs Medical Center, University of Colorado Denver Anschutz Medical Center,
Abstract
Cabozantinib (CABO) after prior immune checkpoint inhibitor (ICI) and tyrosine-kinase inhibitors (TKI) therapy in metastatic renal cell carcinoma (mRCC): Real-world evidence (RWE) from a Moscow observational program.Org: SBIH Moscow Clinical Scientific and Practical Center Named After A.S. Loginov, Moscow, Russian Federation,
Abstract
Exploring the significance of MET overexpression by gene expression profiling versus immunohistochemistry in an EGFR-mutant lung cancer cohort.Org: Medanta Medicity, Gleneagles BGS Hospital, Sahyadri Hospital, HCA Healthcare UK, Metro Hospital,
Product
TMZAbstract
Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO).Org: Nashville, OneOncology, TN, South San Francisco, Genentech,
Abstract
Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.Org: Gustave Roussy Cancer Center, University of Pennsylvania, National Cancer Center Hospital East, Kashiwa, Japan, Seoul National University Bundang Hospital, Yonsei University College of Medicine,
Abstract
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.Org: Dana-Farber Cancer Institute, Gustave Roussy Cancer Center, Clinical Hospital No. 1 of the Poznan University of Medical Sciences, Memorial Sloan Kettering Cancer Center, Hospital Universitario 12 de Octubre,
Abstract
Changes in ctDNA levels as an early indicator of outcomes in advanced NSCLC treated with TKI: Initial findings from a retrospective aggregate analysis of 8 clinical trials.Org: Friends of Cancer Research, Washington, DC, NMD Group, Cancer Research and Biostatistics, Guardant Health, Inc., Takeda Pharmaceuticals U.S.A., Inc.,
Abstract
Depth of radiographic response (DpR) and time to tumor regrowth (TTG) to predict overall survival following anti-VEGF therapy in recurrent glioblastoma.Org: Novartis Pharma AG, F. Hoffmann-La Roche Ltd, Exelixis, Inc., VBL Therapeutics, Dana-Farber Cancer Institute,
Abstract
Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).Org: Johns Hopkins University Bloomberg School of Public Health, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, RI-MUHC,
Abstract
The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program.Org: Durham, NC, Labcorp Oncology, Nykode Therapeutics, Buffalo, Duke University Medical Center,
Abstract
Tepotinib + osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib.Org: Division of Medical Oncology, National Cancer Centre, Singapore, Singapore, Seoul National University Cancer Research Institute, Seoul, Republic of Korea,
Abstract
Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial.Org: City of Hope Comprehensive Cancer Center, SWOG Statistics and Data Management Center, Seattle, WA, University of Washington and Fred Hutchinson Cancer Research Centre, Yale School of Medicine, Yale University,
Abstract
STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer.Org: David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Exelixis, Inc.,
Abstract
Understanding resistance in V600E BRAF advanced colon cancer treated with BRAF inhibitors plus anti-EGFR antibodies +/- MEK inhibitors: The URBAN study.Org: Medical Oncology 1, Venetian Institute of Oncology-IRCCS, Padua, Padua, Italy, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy, Department of Medicine (DIMED) University of Padua and Veneto Institute of Oncology (IOV-IRCCS ),
Abstract
Incorporating long non-coding RNA (lncRNA) into genome-wide biomarker screening for prognostic gene signatures of immunotherapy outcomes.Org: H. Lee Moffitt Cancer Center and Research Institute, Ohio State University Comprehensive Cancer Center, University of Virginia, Charlottesville, VA, USA, University of Colorado Denver Anschutz Medical Center, University of Southern California - Health Sciences Campus,
Abstract
Investigating alterations in cancer driver genes and other potentially targetable mutations in patients with intrahepatic cholangiocarcinoma (iCCA) treated on the randomised phase III multicentre BILCAP clinical trial.Org: UCL-University College London (United Kingdom ), University of Edinburgh Cancer Research UK Centre, Institute of Cancer & Genomic Sciences, University of Birmingham, University of Southampton NHS Foundation Trust, Bill Lyons Informatics Centre, London,
Abstract
Updated molecular analysis of MET exon 14 skipping mutations (METex14) in non-small cell lung cancer (NSCLC).Org: Caris Life Sciences Research and Development, Emory University School of Medicine, University Of California San Diego Ideka Laboratory, Caris Life Sciences, Irving, TX, Penn State Milton S. Hershey Medical Center, Hershey, PA,
Abstract
Comprehensive nationwide study on the prescription of experimental anticancer therapies for compassionate use in children and adolescents in France.Org: Gustave Roussy Cancer Campus, French National Authority for Health, Institut Curie, Saint Cloud, France, IHOPe-CLB, Paediatric Haematology-Oncology Department,
Abstract
Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial.Org: Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, Memorial Sloan Kettering Cancer Center and Weill Cornell College of Medicine,
Abstract
Exploring expression levels of HER2, HER3, MET, Claudin18.2, and MUC16 across 16 cancer types using an artificial intelligence-powered immunohistochemistry analyzer.Org: Oncology Therapeutic Development, Lunit Inc., Samsung Medical Center, Sungkyunkwan University School of Medicine, Chonnam National University Medical School and Hwasun Hospital,
Abstract
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).Org: Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York-Presbyterian Hospital, The Tisch Cancer Institute,
Abstract
Germline mutations in hereditary renal cell carcinoma (RCC) genes among 32,240 patients with all cancer types.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell College of Medicine, Weill Medical College,
Abstract
Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC.Org: University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, MD Anderson Cancer Center,
Abstract
Genomic comparison of MET exon 14 skipping and MET amplified non-small cell lung cancer.Org: Department of Human Oncology, University of Wisconsin, University of Wisconsin, Madison, University of Wisconsin–Madison, University of Wisconsin-Madison Carbone Cancer Center, Tempus Labs, Inc.,
Abstract
Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.Org: St. James’s Hospital, Dana-Farber Cancer Institute, University of Texas MD Anderson Cancer Center, Jefferson Kimmel Cancer Center at Jefferson Health, NCI,
Abstract
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).Org: Illumina, Inc.,
Abstract
CD8 cell PET imaging with 89-Zr-crefmirlimab berdoxam (crefmirlimab) in patients with metastatic renal cell carcinoma (mRCC) receiving checkpoint inhibitors (CPIs): Association with response and tissue CD8 expression.Org: City of Hope National Medical Center, John Wayne Cancer Institute, University of Washington and Fred Hutchinson Cancer Research Centre, CARTI Cancer Center, ImaginAb,
Abstract
EGFR assessment using next generation sequencing as a reflex testing on surgically resected non-squamous non-small cell lung carcinoma.Org: Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, FHU OncoAge, Université Côte d’Azur, CHU Nice,
Abstract
CABIOS trial: A phase Ib study of cabozantinib and nivolumab in combination with abiraterone in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).Org: Washington University School of Medicine in St Louis, Saint Lukes Hospital,
Abstract
Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals.Org: FDA/CDER, U.S. Food and Drug Administration, US Food and Drug Administration, Oncology Center of Excellence, Office of New Drugs,
Abstract
Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial.Org: Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, Department of Oncology, University of Oxford, Oxford, United Kingdom, Division of Pathology and Data Analytics, University of Leeds, Leeds, United Kingdom, Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom, Queen's University Belfast, Belfast, United Kingdom,
Abstract
Survival associations and driver oncogene overlap for copy-number amplifications of ERBB2, KRAS and MET in non-small cell lung cancer.Org: Tom Baker Cancer Center, Calgary, AB, Canada, Caris Life Sciences, Irving, TX, Irving, TX, Phoenix, AZ,
Abstract
Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions.Org: City of Hope- Long Beach Elm, Perlmutter Cancer Center, New York University Langone Health, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Dana-Farber Cancer Institute, Northwestern Medicine Devleopmental Therapeutics Institute,
Abstract
Impact of next generation sequencing on a clinicians’ first line treatment decision in patients with stage IV non-small cell lung cancer.Org: Kaiser Permanente SCPMG, Kaiser Permanente School of Medicine, Kaiser Permanente Oakland Medical Center, Kaiser Permanente Southern California,
Abstract
A master screening study to determine biomarker status and trial eligibility for patients with malignant tumors.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Roche Products Ltd., F. Hoffmann-La Roche Ltd, Genentech, Centro de Investigación y Manejo del Cáncer (CIMCA),
Abstract
Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.Org: EMD Serono Research & Development Institute, Genesis Research, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center,
Abstract
LUNG-IST-127: A pilot phase II study of maintenance cabozantinib plus pembrolizumab for patients with metastatic squamous non-small cell lung cancer (sqNSCLC) with disease control following induction therapy.Org: Department of Hematology Oncology University of Illinois of Chicago College of Medicine, University of Ilinois Chicago, Department of Surgery University of Illinois of Chicago College of Medicine, University of Illinois Chicago, Jesse Brown VAMC,
Abstract
Neoadjuvant immunotherapy in hepatocellular carcinoma: A systematic review and meta-analysis.Org: Bridgeport Hospital, Yale New Haven Health, Bridgeport, CT, UMass Chan Medical School, Shrewsbury, MA,
Abstract
Effects of mutations in SWI/SNF subunits on context-specific prognosis in driver positive and driver negative NSCLC.Org: Caris Life Sciences Research and Development, Caris Life Sciences, Irving, TX, Lombardi Comprehensive Cancer Center, Department of Molecular Pharmacology and Therapeutics,
Abstract
PEMBROCABOSARC: Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas.Org: Institut Bergonie, Institut Bergonié, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Institut Paoli Calmettes, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy,
Abstract
Restaging scans frequency heterogeneity in patients being treated for stage IV non-small cell lung cancer (NSCLC).Org: Mayo Clinic, Jacksonville, FL,
Abstract
Spectrum of acquired KRAS mutations in driver mutation-positive non-small cell lung cancer.Org: Caris Life Sciences, Irving, TX, West Virginia University Health Sciences Center Department of Epidemiology and Biostatistics, Mayo Clinic, Penn State Milton S. Hershey Medical Center, Hershey, PA,
Abstract
Feasibility and utility of the custom RNA-seq for the identification of therapeutic targets and diagnostic biomarkers in glioma.Org: Department of Neurosurgery and Neuro-Oncology, National Cancer Center Research Institute, Tokyo, Japan, National Cancer Center Hospital East, Kashiwa, Japan, Division of Cellular Signaling, National Cancer Center Research Institute, Department of Brain Disease Translational Research,
Abstract
The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.Org: Mount Sinai Health System, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Dana-Farber Cancer Institute, SWOG Statistical Center,
Abstract
Biomarkers to predict the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer with actionable genetic alterations.Org: SAIHST, Sungkyunkwan University of Medicine, Samsung Medical Center,
Abstract
A phase 1b study of crizotinib in combination with temsirolimus in pediatric ALK- or MET-aberrated relapsed or refractory neuroblastoma (ITCC-053): Results of the phase 1 part.Org: Pfizer Global Research and Development, Institut Curie, Saint Cloud, France, University Medical Center Utrecht, Netherlands Cancer Institute, The Royal Marsden Hospital,
Abstract
Real-world testing and treatment patterns among patients with stage IV non-small cell lung cancer: A retrospective observational study.Org: Integra Connect PrecisionQ, Massachusetts General Hospital, Sarah Cannon Research Institute/Tennessee Oncology, Florida Cancer Specialists and Research Institute, Ocala, FL, Thermo Fisher Scientific,
Abstract
Identification of biomarkers for early progression in muscle invasive bladder cancer (MIBC) using real-world data.Org: ConcertAI,
Abstract
Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Yonsei Cancer Center, Yonsei University Health System, Yonsei University College of Medicine,
Abstract
AI-driven real-time patient identification for randomized controlled trials.Org: Mango Sciences, Inc., Boston Pharmaceuticals, Subhash Nagar, Nelamangala, Indiana University – Purdue University Indianapolis,
Abstract
Nivolumab usage patterns combined with TKI for mRCC: Financial toxicity and clinical outcomes from self-paying patients in India—Is low dose an option when access is limited?Org: Christian Medical College & Hospital Vellore, Christian Medical College Vellore, Department of Uro-Oncology, Chongqing University Cancer Hospital, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,
Abstract
Clinical synergy of universal paired tumor genomic and germline sequencing in an unselected, pan-cancer cohort of patients: Greater than the sum of the parts.Org: Invitae, Mayo Clinic, Mayo Clinic Cancer Center Scottsdale, Mayo Clinic in Arizona, Division of Gastroenterology and Hepatology, Mayo Clinic,
Abstract
Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study.Org: Memorial Sloan-Kettering Cancer Center, Knapp Center for Biomedical Discovery, The University of Chicago Medicine Center for Advanced Care at Orland Park, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Thoraxklinik,
Abstract
Analytical performance assessment of ASPYRE-Lung: A new assay for rapid detection of actionable variants from tissue and plasma in NSCLC patients.Org: Biofidelity Ltd,
Abstract
Droplet digital PCR as an alternative method for detecting MET amplification in patients with non-small cell lung cancer.Org: Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Southern Medical University Guangzhou, Southern Medical University,
Abstract
Reality check for precision oncology in squamous cell lung cancer.Org: UAMS-Winthrop Rockefeller Cancer Institute, UAMS Medical College Physicians Group,
Abstract
Whole exome sequencing of sinonasal cancers.Org: The Ohio State University Wexner Medical Center, The Ohio State University - James Cancer Hospital, The Ohio State University-James Cancer Hospital Solove Research Institute, The Ohio State University - James Cancer Hospital and Solove Research Institute, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center,
Abstract
Characteristics and predictive modeling of HER2 mutation in patients with non-small cell lung cancer.Org: Mayo Clinic, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, City of Hope National Medical Center, Daiichi Sankyo Inc., Daiichi Sankyo Co. Ltd.,
Abstract
Gaps and factors in patient awareness of biomarker test timing and purpose in non-small cell lung cancer (NSCLC): Baseline assessment for implementation of 4R Oncology model.Org: Department of Medicine, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, Center for Business Models on Healthcare, Glencoe, IL, Johns Hopkins Hospital, Baltimore, MD, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, Emory University Hospital, Atlanta, GA, Emory University, Atlanta, GA, Grady Memorial Hospital, Atlanta, GA, SOMC Cancer Center, Portsmouth, OH, SOUTHERN OHIO MEDICAL CENTER, Portsmouth, OH, Southern Ohio Medical Center, Portsmouth, OH, Northwestern Memorial Hospital, Chicago, IL, Northwestern University, Chicago, IL, Wake Forest School of Medicine, Winston-Salem, NC, LUNGevity Foundation, Bethesda, MD, Association of Community Cancer Centers, Rockville, MD, Association of Community Cancer Centers (ACCC), Rockville, MD, Center for Business Models in Healthcare, Glencoe, IL,
Abstract
Prognostic stratification and outcome of metastatic NSCLC based on activating mutation profile and PD-L1 status.Org: The University of Texas Health Science Center at Houston, UTHealth Houston, McGovern Medical School,
Abstract
Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study—Updated safety and identification of the recommended phase 2 dose.Org: Drug Development Unit at Royal Marsden Hospital/Institute of Cancer Research, Sutton, United Kingdom, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, Yonsei University College of Medicine, Seoul, Korea, Republic of (South), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada,
Abstract
Mutation profiling of gliomas based on sex, age, and family history.Org: Shenzhen Longgang Third People's Hospital, Shenzhen, China, Haplox biotechnology Co., Ltd., Shenzhen, Guangdong, China, HaploX Biottechnology Co., Ltd., Shenzhen, Guangdong, China, HaploX Biotechnology, Shenzhen, China, HaploX Biotechnology Co., Ltd, Shenzhen, Guangdong, China, Tianjin Union Medical Center, Tianjin, Tianjin, China, Shenzhen, Guangdong, China, HaploX Biotechnology, Shenzhen, China,
Abstract
Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University Hospital of Cologne, China Medical University Hospital, Bhaktivedanta Hospital And Research Centre and School of Consciouness,
Abstract
FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes.Org: National Cancer Institute, Vilnius, Lithuania, Nihon Medi-Physics, Cleveland Clinic Taussig Cancer Instititute, Medical College of Wisconsin, NYU Langone Laura and Isaac Perlmutter Cancer Center,
Abstract
Examining molecular testing practices and targeted therapy use in advanced/metastatic non-small cell lung cancer (mNSCLC): A quality improvement initiative across ten community cancer centers.Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, PRIME Education LLC,
Abstract
Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction (PCR) versus next-generation sequencing (NGS) testing strategies in metastatic non-small cell lung cancer (mNSCLC).Org: University of Chicago, Janssen Scientific Affairs, Analysis Group, Inc.,
Abstract
Retrospective analysis of the multikinase inhibitor (MKI) pazopanib in differentiated thyroid carcinoma (DTC) in the beyond-first-line setting.Org: Mayo Clinic, University of Missouri–Kansas City, Mayo Clinic Florida,
Abstract
Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study.Org: US Oncology Research/New York Oncology Hematology, Albany, NY, US Oncology Research/Oncology Associates of Oregon P.C., Eugene, OR, US Oncology Research/Virginia Oncology Associates, Newport News, VA, US Oncology Research/Oncology Hematology Care, Inc., The Woodlands, TX, US Oncology Research/Virginia Cancer Specialists, Fairfax, VA,
Abstract
Tumor immune microenvironment in BRAF V600E mutant lung adenocarcinoma.Org: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Pekin, Beijing, China, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Beijing, China, National Cancer Center/National Clinical Research Center for Cancer/Caner Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Department of diagnostic radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Genecast Biotechnology Co., Ltd., Wuxi, China,
Abstract
Analysis on real-world chemotherapy outcomes in patients (pts) with tyrosine kinase inhibitor (TKI) resistant advanced EGFR-mutant non–small-cell lung cancer (NSCLC) in the United States.Org: Merck, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Copy number variation (CNV) calling of MET, MYC, and ERBB2 using PiVAT bioinformatic platform.Org: Shanghai Zhengu Biological Technology Co., Ltd, Pillar Biosciences Inc.,
Abstract
Patient characteristics, treatment patterns, and clinical outcomes among patients with de novo advanced or metastatic (stage IIIB–IV) non-small cell lung cancer in a real-world setting.Org: EMD Serono Research & Development Institute, Rockland, MA, Genesis Research, Hoboken, NJ, Memorial Sloan Kettering Cancer Center,
Abstract
Analysis of cell-free DNA (cfDNA) fragmentomes and prediction scores across distinct molecular subtypes.Org: Delfi Diagnostics, Inc., DELFI Diagnostics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Johns Hopkins University School of Medicine, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
High-throughput drug screening (HTDS) of patient-derived tumor organoids (PTDO) from advanced gastrointestinal malignancies: Response and identification of novel therapeutic options.Org: Weill Cornell Medical College University, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, NewYork-Presbyterian/Weill Cornell Medical Center, Joan and Sanford I Weill Medical College of Cornell University, NYP/Columbia,
Abstract
Real-world assessment of treatment effectiveness in patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping (METex14).Org: University of Iowa Hospitals & Clinics, Carver College of Medicine - University of Iowa, Iowa City, IA, RTI Health Solutions, Research Triangle Park, NC,
Abstract
Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib.Org: Memorial Sloan Kettering Cancer Center, Department of Pathology, Aberdeen University Medical School & Aberdeen Royal Infirmary, Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Medical System & Icahn School of Medicine, Department of Thoracic Oncology, Peking University Cancer Hospital, IRCCS Humanitas Research Hospital, Rozzano, Italy,
Abstract
Does the landscape of comprehensive genomic profiling in patients with advanced stage lung cancer in India differ from data from the western countries.Org: Fortis Cancer Institute, New Delhi, India, Fortis Cancer Institute, Bangalore Karnataka, India, Fortis Cancer Institute, Gurgaon, Haryana, India, Fortis Cancer Institute, Delhi, India, Fortis Hospital and research centre, New Delhi, India,
Abstract
Phase 1b study of HS-10241 combined with almonertinib in pre-treated advanced non-small cell lung cancer (NSCLC) harboring EGFR mutation.Org: Hansoh Pharmaceutical Group Co, Ltd., Hansoh Pharmaceutical Group Co. Ltd.,
Abstract
Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).Org: Tisch Cancer Institute, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,
Abstract
Correlations between overall response rate, progression-free survival and overall survival with kinase inhibitors in radioiodine-refractory differentiated thyroid cancers: A systematic review and meta-analysis.Org: One Brooklyn Health/Brookdale University Hospital and Medical Center, Brooklyn ImmunoTherapeutics, Nykode Therapeutics,
Abstract
A robust and accurate method to detect MET Exon 14–skipping mutation in pan-cancer samples using an NGS-based RNAseq approach.Org: ChosenMed Technology (Beijing) Co.Ltd, ChosenMed Technology (Beijing) Co., Ltd., ChosenMed Technology (Zhejiang) Co., Ltd.,
Abstract
Mutational profiling of true single circulating tumor cells (sCTC) in metastatic lung cancer to determine genomic heterogeneity and drug-resistance signatures.Org: OneCell Diagnostics, Cupertino, CA, OneCell Dx, Pune, Tata Memorial Hospital (HBNI),
Abstract
Treatment outcomes in patients (pts) with advanced/metastatic non‑small cell lung cancer (NSCLC) harboring MET amplification as a secondary oncogenic driver.Org: West Cancer Center & Research Institute, Merck, Global Clinical Development, the healthcare business of Merck KGaA, Darmstadt, Germany,
Abstract
Liquid and tissue profiling of somatic mutational landscape of non-small cell lung cancer from an Indian cohort.Org: Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, NY, India, Adana Acıbadem Hospital, Adana, Turkey, St Bartholomew's Hospital, London, United Kingdom, Fortis Cancer Institute, New Delhi, India, Imperial College London, London, United Kingdom,
Abstract
Real world early experience of precision neoadjuvant systemic therapy in patients with resectable NSCLC: Single institution experiences and perspectives.Org: University of California, Davis, UC Davis Comprehensive Cancer Center, Sacramento, CA,
Abstract
Biomarker testing and treatment patterns in US patients (pts) with advanced/metastatic non‑small cell lung cancer (NSCLC) harboring MET amplification.Org: West Cancer Center & Research Institute, Merck, ConcertAI,
Abstract
Comprehensive plasma genotyping reveals mutational signatures that confer resistance to tyrosine kinase inhibitors (TKI) in patients with advanced lung cancer.Org: OneCell Dx, Tata Memorial Hospital (HBNI), OneCell Diagnostics, School of Consciousness, MIT WPU, Indx Technology,
Abstract
Evaluation of the prevalence of MET and protein tyrosine kinase 7 expression in non-small cell lung cancer to evaluate overlap of ADC antigens.Org: AbbVie Inc., North Chicago, IL, University of Colorado Denver Department of Radiation Oncology, University Hospital Birmingham NHS Foundation Trust, City of Hope Comprehensive Cancer Center, Shanghai Lung Cancer Center,
Abstract
Genomic profiling in advanced NSCLC in Italy: First results of NERoNE (NSCLC Emilia Romagna Next Generation Sequencing Evaluation) project.Org: University of Modena and Reggio Emilia, Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori (IRST), Molecular Pathology Laboratory, Program Clinical and Experimental Medicine,
Abstract
Genomic characterization of papillary thyroid carcinoma in Chinese Shandong population.Org: Department of Breast and Thyroid Surgery, Shandong Provincial Hospital, Jinan, China, Department of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Department of Thyroid and Breast, The 960th hospital of PLA, Jinan, China, Department of External Medicine, Jinan Huaiyin People's Hospital, Jinan, China, Second Department of Breast Diseases/Second Department of Thyroid Diseases, The Second People's Hospital of Shandong Province, Jinan, China,
Abstract
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: The IMMINENT study.Org: University of Verona, Oncology Section, Azienda Ospedaliera Universitaria Integrata di Verona, Ospedale San Bortolo Azienda ULSS8 Berica - Distretto Est, Santa Chiara Hospital, Trento, Italy, Policlinico Universitario Gaspare Rodolico,
Abstract
Real-life use of cabozantinib as front-line therapy in metastatic renal cell carcinoma: The CabFRONT (Meet-URO 24) study.Org: Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Department of Health Sciences, University of Florence, Florence, Italy, Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy, Oncology Unit, Foundation Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy,
Abstract
Clinical benefit of personalized treatment following high throughput sequencing in metastatic melanoma: A national retrospective study.Org: Dermatology and Skin Cancer Department, AP-HM Marseille, Dermatology Departement, Cochin Hospital, APHP,Université Paris Cité, Paris, France, CHU de Bordeaux, Cochin Hospital,